405 related articles for article (PubMed ID: 23071360)
1. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy.
Meijer TW; Kaanders JH; Span PN; Bussink J
Clin Cancer Res; 2012 Oct; 18(20):5585-94. PubMed ID: 23071360
[TBL] [Abstract][Full Text] [Related]
2. Metabolic targeting of HIF-dependent glycolysis reduces lactate, increases oxygen consumption and enhances response to high-dose single-fraction radiotherapy in hypoxic solid tumors.
Leung E; Cairns RA; Chaudary N; Vellanki RN; Kalliomaki T; Moriyama EH; Mujcic H; Wilson BC; Wouters BG; Hill R; Milosevic M
BMC Cancer; 2017 Jun; 17(1):418. PubMed ID: 28619042
[TBL] [Abstract][Full Text] [Related]
3. Recent agents targeting HIF-1α for cancer therapy.
Hu Y; Liu J; Huang H
J Cell Biochem; 2013 Mar; 114(3):498-509. PubMed ID: 22961911
[TBL] [Abstract][Full Text] [Related]
4. Eicosanoids and other lipid mediators and the tumor hypoxic microenvironment.
Krishnamoorthy S; Honn KV
Cancer Metastasis Rev; 2011 Dec; 30(3-4):613-8. PubMed ID: 22042480
[TBL] [Abstract][Full Text] [Related]
5. KNK437, abrogates hypoxia-induced radioresistance by dual targeting of the AKT and HIF-1α survival pathways.
Oommen D; Prise KM
Biochem Biophys Res Commun; 2012 May; 421(3):538-43. PubMed ID: 22521642
[TBL] [Abstract][Full Text] [Related]
6. [Angiogenic inhibitors and radiotherapy: from the concept to the clinical trial].
Cohen-Jonathan Moyal E
Cancer Radiother; 2009 Oct; 13(6-7):562-7. PubMed ID: 19695923
[TBL] [Abstract][Full Text] [Related]
7. Cell-permeable hypoxia-inducible factor-1 (HIF-1) antagonists function as tumor radiosensitizers.
Shi M; Guo XT; Shu MG; Chen FL; Li LW
Med Hypotheses; 2007; 69(1):33-5. PubMed ID: 17280792
[TBL] [Abstract][Full Text] [Related]
8. Significance of HIF-1-active cells in angiogenesis and radioresistance.
Harada H; Kizaka-Kondoh S; Li G; Itasaka S; Shibuya K; Inoue M; Hiraoka M
Oncogene; 2007 Nov; 26(54):7508-16. PubMed ID: 17563752
[TBL] [Abstract][Full Text] [Related]
9. The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis.
Lum JJ; Bui T; Gruber M; Gordan JD; DeBerardinis RJ; Covello KL; Simon MC; Thompson CB
Genes Dev; 2007 May; 21(9):1037-49. PubMed ID: 17437992
[TBL] [Abstract][Full Text] [Related]
10. The role of the hypoxia-inducible factor in tumor metabolism growth and invasion.
Brahimi-Horn C; Pouysségur J
Bull Cancer; 2006 Aug; 93(8):E73-80. PubMed ID: 16935775
[TBL] [Abstract][Full Text] [Related]
11. Radiation and inhibition of angiogenesis by canstatin synergize to induce HIF-1alpha-mediated tumor apoptotic switch.
Magnon C; Opolon P; Ricard M; Connault E; Ardouin P; Galaup A; Métivier D; Bidart JM; Germain S; Perricaudet M; Schlumberger M
J Clin Invest; 2007 Jul; 117(7):1844-55. PubMed ID: 17557121
[TBL] [Abstract][Full Text] [Related]
12. High glucose concentrations attenuate hypoxia-inducible factor-1alpha expression and signaling in non-tumor cells.
Dehne N; Hintereder G; Brüne B
Exp Cell Res; 2010 Apr; 316(7):1179-89. PubMed ID: 20184881
[TBL] [Abstract][Full Text] [Related]
13. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity.
Moeller BJ; Dreher MR; Rabbani ZN; Schroeder T; Cao Y; Li CY; Dewhirst MW
Cancer Cell; 2005 Aug; 8(2):99-110. PubMed ID: 16098463
[TBL] [Abstract][Full Text] [Related]
14. Targeting the hypoxia-inducible factor (HIF) pathway in cancer.
Poon E; Harris AL; Ashcroft M
Expert Rev Mol Med; 2009 Aug; 11():e26. PubMed ID: 19709449
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting hypoxia-inducible factor 1 for cancer therapy.
Melillo G
Mol Cancer Res; 2006 Sep; 4(9):601-5. PubMed ID: 16940159
[TBL] [Abstract][Full Text] [Related]
16. Modulation of glucose metabolism inhibits hypoxic accumulation of hypoxia-inducible factor-1alpha (HIF-1alpha).
Staab A; Löffler J; Said HM; Katzer A; Beyer M; Polat B; Einsele H; Flentje M; Vordermark D
Strahlenther Onkol; 2007 Jul; 183(7):366-73. PubMed ID: 17609869
[TBL] [Abstract][Full Text] [Related]
17. Tumour glycolysis: the many faces of HIF.
Kelly C; Smallbone K; Brady M
J Theor Biol; 2008 Sep; 254(2):508-13. PubMed ID: 18639251
[TBL] [Abstract][Full Text] [Related]
18. Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy.
Sun X; Kanwar JR; Leung E; Lehnert K; Wang D; Krissansen GW
Gene Ther; 2001 Apr; 8(8):638-45. PubMed ID: 11320410
[TBL] [Abstract][Full Text] [Related]
19. NADPH oxidase subunit 4 mediates cycling hypoxia-promoted radiation resistance in glioblastoma multiforme.
Hsieh CH; Wu CP; Lee HT; Liang JA; Yu CY; Lin YJ
Free Radic Biol Med; 2012 Aug; 53(4):649-58. PubMed ID: 22713363
[TBL] [Abstract][Full Text] [Related]
20. Targeting the molecular basis for tumour hypoxia.
Carroll VA; Ashcroft M
Expert Rev Mol Med; 2005 Apr; 7(6):1-16. PubMed ID: 15831177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
